Last reviewed · How we verify
Dulcotil (SULOCTIDIL)
At a glance
| Generic name | SULOCTIDIL |
|---|---|
| Drug class | suloctidil |
| Target | Adenosine receptor A3, Substance-K receptor, 5-hydroxytryptamine receptor 1A |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dulcotil CI brief — competitive landscape report
- Dulcotil updates RSS · CI watch RSS